ACP3 and prostate cancer: Given the high and selective expression of ACP3 in prostate cancer lesions,[30] the use of S‐A2855/B725 as tumor‐targeting moiety may lead to the development of radioligand theranostics for PCa with low uptake in salivary glands and kidney.